EGFR-mutated NSCLC: practice-changing results and other notable findings

被引：0
|
作者：
不详
机构：
来源：
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY | 2023年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S188 / S192
页数：5
相关论文
共 50 条
  • [21] Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?
    Qiao, Meng
    Jiang, Tao
    Liu, Xinyu
    Mao, Shiqi
    Zhou, Fei
    Li, Xuefei
    Zhao, Chao
    Chen, Xiaoxia
    Su, Chunxia
    Ren, Shengxiang
    Zhou, Caicun
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (08) : 1267 - 1288
  • [22] Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC
    Lu, Shun
    Kato, Terufumi
    Dong, Xiaorong
    Ahn, Myung-Ju
    Quang, Le-Van
    Soparattanapaisarn, Nopadol
    Inoue, Takako
    Wang, Chih-Liang
    Huang, Meijuan
    Yang, James Chih-Hsin
    Cobo, Manuel
    Ozguroglu, Mustafa
    Casarini, Ignacio
    Khiem, Dang-Van
    Sriuranpong, Virote
    Cronemberger, Eduardo
    Takahashi, Toshiaki
    Runglodvatana, Yotsawaj
    Chen, Ming
    Huang, Xiangning
    Grainger, Ellie
    Ghiorghiu, Dana
    van der Gronde, Toon
    Ramalingam, Suresh S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024,
  • [23] Osimertinib also improves overall survival in EGFR-mutated NSCLC
    Lichert, Frank
    PNEUMOLOGIE, 2024, 78 (03): : 143 - 143
  • [24] Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
    Ramalingam, S. S.
    Vansteenkiste, J.
    Planchard, D.
    Cho, B. C.
    Gray, J. E.
    Ohe, Y.
    Zhou, C.
    Reungwetwattana, T.
    Cheng, Y.
    Chewaskulyong, B.
    Shah, R.
    Cobo, M.
    Lee, K. H.
    Cheema, P.
    Tiseo, M.
    John, T.
    Lin, M-C
    Imamura, F.
    Kurata, T.
    Todd, A.
    Hodge, R.
    Saggese, M.
    Rukazenkov, Y.
    Soria, J-C
    Boyer, Michael
    Lee, Chee
    Hughes, Brett
    O'Byrne, Kenneth
    Briggs, Peter
    Milward, Michael
    John, Thomas
    Demedts, Ingel
    Vansteenkiste, Johan
    Bustin, Frederique
    Barrios, Carlos Henrique
    Timcheva, Constanta
    Butts, Charles
    Goss, Glenwood
    Juergens, Rosalyn
    Leighl, Natasha
    Cheng, Susanna
    Burkes, Ronald
    Zhou, Caicun
    Zhang, Helong
    Shu, Yongqian
    Cheng, Ying
    Zhou, Qing
    Li, Wei
    Feng, Guosheng
    He, Yong
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (01): : 41 - 50
  • [25] Chemotherapy in EGFR-mutated NSCLC: optimizing combinations with TKIs and amivantamab
    Rosell, Rafael
    Gonzalez-Cao, Maria
    NATURE REVIEWS CLINICAL ONCOLOGY, 2024, 21 (03) : 169 - 170
  • [26] Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
    Masahiro Tsuboi
    Roy S. Herbst
    Thomas John
    Terufumi Kato
    Margarita Majem
    Christian Grohé
    Jie Wang
    Jonathan W. Goldman
    Shun Lu
    Filippo de Marinis
    Frances A. Shepherd
    Ki Hyeong Lee
    Nhieu Thi Le
    Arunee Dechaphunkul
    Dariusz Kowalski
    Laura Bonanno
    Manuel Dómine
    Lynne Poole
    Ana Bolanos
    Yuri Rukazenkov
    Yi-Long Wu
    Targeted Oncology, 2024, 19 : 131 - 134
  • [27] Simulation in the Management of EGFR-Mutated Advanced NSCLC: Seeing Beyond Age
    Carey, Christine
    Herrmann, Tara
    Warters, Martin
    Blevins, Douglas
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S270 - S270
  • [28] Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC
    Novak, Jennifer
    Salgia, Ravi
    West, Howard
    Villalona-Calero, Miguel A.
    Sampath, Sagus
    Williams, Terence
    Villaflor, Victoria
    Massarelli, Erminia
    Pathak, Ranjan
    Koczywas, Marianna
    Chau, Brittney
    Amini, Arya
    CANCERS, 2022, 14 (16)
  • [29] Clinical outcomes in Black patients with EGFR-mutated NSCLC treated with osimertinib
    Belani, Neel
    Rizwan, Farsha
    Hasler, Jill
    Bauman, Jessica
    Mitchell, Khadijah
    Borghaei, Hossein
    Bodor, Joseph N.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2024, 33 (09)
  • [30] Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC
    Cho, Byoung C.
    Lu, Shun
    Felip, Enriqueta
    Spira, Alexander I.
    Girard, Nicolas
    Lee, Jong-Seok
    Lee, Se-Hoon
    Ostapenko, Yurii
    Danchaivijitr, Pongwut
    Liu, Baogang
    Alip, Adlinda
    Korbenfeld, Ernesto
    Mourao Dias, Josiane
    Besse, Benjamin
    Lee, Ki-Hyeong
    Xiong, Hailin
    How, Soon-Hin
    Cheng, Ying
    Chang, Gee-Chen
    Yoshioka, Hiroshige
    Yang, James C. -H.
    Thomas, Michael
    Nguyen, Danny
    Ou, Sai-Hong I.
    Mukhedkar, Sanjay
    Prabhash, Kumar
    D'Arcangelo, Manolo
    Alatorre-Alexander, Jorge
    Vazquez Limon, Juan C.
    Alves, Sara
    Stroyakovskiy, Daniil
    Peregudova, Marina
    Sendur, Mehmet A. N.
    Yazici, Ozan
    Califano, Raffaele
    Gutierrez Calderon, Vanesa
    de Marinis, Filippo
    Passaro, Antonio
    Kim, Sang-We
    Gadgeel, Shirish M.
    Xie, John
    Sun, Tao
    Martinez, Melissa
    Ennis, Mariah
    Fennema, Elizabeth
    Daksh, Mahesh
    Millington, Dawn
    Leconte, Isabelle
    Iwasawa, Ryota
    Lorenzini, Patricia
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (16): : 1486 - 1498
12345